UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors

Cancers, 2019-08, Vol.11 (9), p.1262

2019

Volltextzugriff (PDF)

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

Cancer cell, 2012-11, Vol.22 (5), p.668-682

2012

Volltextzugriff (PDF)

Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

Clinical cancer research, 2010-07, Vol.16 (13), p.3329-3334

2010

Volltextzugriff (PDF)

Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (3), p.747-762

2021

Volltextzugriff (PDF)

Perturbation biology: inferring signaling networks in cellular systems

PLoS computational biology, 2013-12, Vol.9 (12), p.e1003290

2013

Volltextzugriff (PDF)

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer

Cancer discovery, 2015-09, Vol.5 (9), p.960-971

2015

Volltextzugriff (PDF)

Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition

PloS one, 2019-06, Vol.14 (6), p.e0217399

2019

Volltextzugriff (PDF)

V⁶⁰⁰EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

Proceedings of the National Academy of Sciences - PNAS, 2009-03, Vol.106 (11), p.4519-4524

2009

Volltextzugriff (PDF)

Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors

Cancer research (Chicago, Ill.), 2020-12, Vol.80 (23), p.5367-5379

2020

Volltextzugriff (PDF)

RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

Proceedings of the National Academy of Sciences - PNAS, 2010-08, Vol.107 (33), p.14903-14908

2010

Volltextzugriff (PDF)

Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum

The American journal of surgical pathology, 2018-09, Vol.42 (9), p.1166-1181

2018

Volltextzugriff (PDF)

{V600E} BRAF$is Associated with Disabled Feedback Inhibition of RAF–MEK Signaling and Elevated Transcriptional Output of the Pathway

Proceedings of the National Academy of Sciences - PNAS, 2009-03, Vol.106 (11), p.4519-4524

2009

Volltextzugriff (PDF)

MEK inhibition enhances the antitumor effect of radiation therapy in NF1-deficient glioblastoma

Molecular cancer therapeutics, 2024-05

2024

Volltextzugriff (PDF)

From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor

Genes, 2020-06, Vol.11 (6), p.691

2020

Volltextzugriff (PDF)

Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence

Cancer research (Chicago, Ill.), 2014-04, Vol.74 (8), p.2340-2350

2014

Volltextzugriff (PDF)

The promise of signal transduction in genetically driven sarcomas of the nerve

Experimental neurology, 2018-01, Vol.299 (Pt B), p.317-325

2018

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors

Clinical cancer research, 2019-12, Vol.25 (24), p.7294-7302

2019

Volltextzugriff (PDF)

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors

Cancer discovery, 2012-10, Vol.2 (10), p.934-947

2012

Volltextzugriff (PDF)

Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer

Cancer research (Chicago, Ill.), 2010-07, Vol.70 (14), p.5901-5911

2010

Volltextzugriff (PDF)

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

Neuro-oncology (Charlottesville, Va.), 2022-10, Vol.24 (10), p.1776-1789

2022

Volltextzugriff (PDF)

Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance

Clinical cancer research, 2012-07, Vol.18 (13), p.3552-3561

2012

Volltextzugriff (PDF)

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Cancer research (Chicago, Ill.), 2010-03, Vol.70 (6), p.2264-2273

2010

Volltextzugriff (PDF)

Socioeconomic and health care coverage disparities in children, adolescents, and young adults with sarcoma

Pediatric blood & cancer, 2020-12, Vol.67 (12), p.e28708-n/a

2020

Volltextzugriff (PDF)

Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells

eLife, 2015-08, Vol.4

2015

Volltextzugriff (PDF)

BRAF mutation predicts sensitivity to MEK inhibition

Nature, 2006-01, Vol.439 (7074), p.358-362

2006

Volltextzugriff (PDF)

1 – 25 von 146

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(139)
Mit Volltextzugriff
(123)

Publikationsform

Artikel
(145)
Buchkapitel
(1)

Sprache

Englisch
(146)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

Science & Technology
(78)
Life Sciences & Biomedicine
(70)
Humans
(63)
Oncology
(50)
Tumors
(28)
Cell Line, Tumor
(26)
Mutation
(25)
Animals
(23)
Mice
(20)
Female
(19)
Proto-Oncogene Proteins B-Raf - Genetics
(17)
Pediatrics
(15)
Patients
(14)
Chemotherapy
(13)
Kinases
(13)
Signal Transduction
(13)
Cancer
(12)
Male
(12)
Child
(11)
Melanoma
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors

Perturbation biology: inferring signaling networks in cellular systems

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer

Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition

V⁶⁰⁰EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors

RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum

{V600E} BRAF$is Associated with Disabled Feedback Inhibition of RAF–MEK Signaling and Elevated Transcriptional Output of the Pathway

MEK inhibition enhances the antitumor effect of radiation therapy in NF1-deficient glioblastoma

From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor

Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence

The promise of signal transduction in genetically driven sarcomas of the nerve

A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors

Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Socioeconomic and health care coverage disparities in children, adolescents, and young adults with sarcoma

Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells

BRAF mutation predicts sensitivity to MEK inhibition

Suchergebnisse filtern